Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 64 от 154

Набира участници Фаза 1/2

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

Von Willebrand Diseases

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

Начало: 16.03.2023 Край: 01.12.2029 Възраст: 12–60 г. Лечение

Australia, Brazil, Canada +4 Vega Therapeutics, Inc NCT05776069

Набира участници

Observational Study Protocol: LIVER-R

Hepatobiliary Cancers

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence).

Начало: 16.03.2023 Край: 30.12.2030 Възраст: 18–130 г.

Australia, Belgium, Brazil +17 AstraZeneca NCT06252753

Набира участници Фаза 1/2

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Prostate Cancer Metastatic Castration-resistant Prostate Cancer Metastatic Hormone Sensitive Prostate Cancer

This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of \[212Pb\]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D). The Phase 2a expansion aims to assess the efficacy and safety of \[212Pb\]Pb-ADVC001 at the RP2 doses in 3 participant groups.

Начало: 15.03.2023 Край: 01.06.2029 Възраст: от 18 г. Лечение

Australia AdvanCell Pty Limited NCT05720130

Набира участници Фаза 3

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Начало: 15.03.2023 Край: 01.05.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +19 AbbVie NCT05445778

Набира участници Фаза 1/2

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Clear Cell Renal Cell Cancer (ccRCC) Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer (CRC) Urothelial Carcinoma (UC) +5

The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC.

Начало: 14.03.2023 Край: 01.03.2029 Възраст: от 18 г. Лечение

Australia, France ITM Oncologics GmbH NCT05706129

Набира участници

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

Cancer of Stomach Oesophageal Cancer Gastric Cancer Gastric Adenocarcinoma +5

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

Начало: 14.03.2023 Край: 14.09.2028 Възраст: от 18 г.

Australia Western Sydney Local Health District NCT05804331

Набира участници Фаза 1/2

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

B-cell Lymphoma Non-Hodgkin Lymphoma B-cell Malignancy Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) +4

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

Начало: 10.03.2023 Край: 01.02.2030 Възраст: от 18 г. Лечение

Australia, United States CRISPR Therapeutics AG NCT05643742

Набира участници Фаза 3

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Alpha1-Antitrypsin Deficiency

The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.

Начало: 06.03.2023 Край: 14.08.2030 Възраст: 18–75 г. Лечение

Australia, Belgium, Brazil +12 Takeda NCT05677971

Набира участници Фаза 2/3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

High Grade Osteosarcoma Localized Osteosarcoma Metastatic Osteosarcoma Secondary Osteosarcoma

This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients with newly diagnosed osteosarcoma. Cabozantinib is in a class of medications called kinase inhibitors which block protein signals affecting new blood vessel formation and the ability to activate growth signaling pathways. This may help slow the growth of tumor cells. The drugs used in standard chemotherapy for this trial are methotrexate, doxorubicin, and cisplatin (MAP). Methotrexate stops cells from making DNA and may kill tumor cells. It is a type of antimetabolite. Doxorubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of tumor cells in the body. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Adding cabozantinib to standard chemotherapy may work better in treating newly diagnosed osteosarcoma.

Начало: 03.03.2023 Край: 20.03.2030 Възраст: до 40 г. Лечение

Australia, Canada, New Zealand +1 National Cancer Institute (NCI) NCT05691478

Набира участници

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

Tricuspid Regurgitation Tricuspid Valve Disease Tricuspid Valvular Disorders

The purpose of this clinical study is to collect safety and efficacy data of the VDyne System to support Conformitè Europëenne (CE) Mark of the VDyne System.

Начало: 01.03.2023 Край: 30.12.2030 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +6 VDyne, Inc. NCT05797519

Набира участници Фаза 1

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors Relapse/Refractory Lymphoma

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Начало: 01.03.2023 Край: 31.03.2026 Възраст: от 18 г. Лечение

Australia, China EpimAb Biotherapeutics (Suzhou)Co., Ltd. NCT05607498

Набира участници

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Arrhythmias, Cardiac Breast Cancer Prostatic Cancer Brain Cancer +5

This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

Начало: 28.02.2023 Край: 31.01.2026 Възраст: от 18 г.

Australia University of Sydney NCT05184790

Набира участници Фаза 3

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Areata Alopecia Alopecia Hypotrichosis Hair Diseases +2

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.

Начало: 27.02.2023 Край: 01.02.2030 Възраст: 6–17 г. Лечение

Argentina, Australia, Canada +9 Eli Lilly and Company NCT05723198

Набира участници Фаза 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade Glioma Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma Pediatric Low-grade Glioma

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.

Начало: 27.02.2023 Край: 01.06.2031 Възраст: до 25 г. Лечение

Australia, Belgium, Brazil +24 Day One Biopharmaceuticals, Inc. NCT05566795

Набира участници Фаза 1/2

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.

Начало: 27.02.2023 Край: 12.05.2027 Възраст: 18–65 г. Лечение

Australia, Belgium, Canada +7 Vertex Pharmaceuticals Incorporated NCT05668741

Набира участници

Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment

Heart Failure Valve Heart Disease

Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.

Начало: 24.02.2023 Край: 30.06.2026 Възраст: от 45 г. Диагностика

Australia Baker Heart and Diabetes Institute NCT05558605

Набира участници Фаза 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations HGG LGG Solid Tumors

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

Начало: 21.02.2023 Край: 28.12.2026 Възраст: от 10 г. Лечение

Australia, Canada, France +8 Fore Biotherapeutics NCT05503797

Набира участници Фаза 1

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Colorectal Cancer Gastric Cancer Ovarian Cancer

This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS) colorectal cancer, or gastric or ovarian cancer. The study is run in 2 parts. Phase 1a is dose escalation IVX037 monotherapy and Phase 1b is IVX037 with checkpoint inhibitor, sintilimab.

Начало: 17.02.2023 Край: 30.11.2028 Възраст: 18–85 г. Лечение

Australia ImmVirx Pty Ltd NCT05427487

Набира участници Фаза 4

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

Alcohol Use Disorder (AUD)

To explore the effectiveness of n-acetylcysteine in improving treatment outcomes for alcohol use disorder in a double-blind randomised placebo-controlled trial.

Начало: 16.02.2023 Край: 01.11.2026 Възраст: 18–70 г. Лечение

Australia University of Sydney NCT05408247

Набира участници Фаза 3

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Ischemic Stroke; Ischemic Attack, Transient

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Начало: 15.02.2023 Край: 09.12.2026 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +40 Janssen Research & Development, LLC NCT05702034

1 … 62 63 64 65 66 … 154